Dechra to launch new VetorylÒ double divisible flavoured tablet range

Dechra has announced it is to extend its popular VetorylÒ range with the launch of Vetoryl Flavoured Tablets for Dogs – its double divisible, flavoured tablets for the treatment of canine Cushing’s syndrome.

Soon to be available alongside the Vetoryl 5mg, 10mg, 30mg, 60mg and 120mg hard capsules, the new Vetoryl Flavoured Tablets for Dogs product range will provide additional dosing flexibility. The flavoured range will include Vetoryl 20mg, 30mg and 60mg double divisible, hydrolysed chicken flavoured tablets featuring SmartTabÔ technology, which will allow the tablets to be easily divided into halves or quarters to aid flexible dosing. The new Vetoryl tablets will be available in packs of 30 tablets.

Vetoryl has been on the market for 20 years with over 300 million capsules sold since its launch. Featuring trilostane as its active ingredient, Vetoryl is licensed for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s syndrome) in dogs. The product is supported by a combination of Dechra’s extensive technical endocrinology experience and its comprehensive support initiatives. These include access to over 30 technical experts across Europe and a wide range of resources consisting of free online interactive courses on Cushing’s syndrome on the Dechra Academy and Dechra’s Endocrinology App which features a diagnostic algorithm for Cushing’s developed in conjunction with the Royal Veterinary College using data from the VetCompass database. The App helps vets diagnose and manage Addison’s disease (hypoadrenocorticism) and feline hyperthyroidism, as well as Cushing’s syndrome. Dechra’s resources also include its Suspecting Cushing’s website for pet owners, which features a handy symptom checklist, together with the Cushing’s Monitoring App for owners of Vetoryl-treated dogs to help simplify the management of Cushing’s, improve compliance with medication and increase engagement in the dog’s care.

Thomas Johnson, Vetoryl brand manager at Dechra, comments: “We are delighted that Vetoryl Flavoured Tablets for Dogs will soon be available, which will provide vets and pets owners with easy to administer, flavoured tablets to provide additional dosing flexibility. This, together with our commitment to providing extensive technical support and resources, will ensure that Vetoryl continues to be the UK’s leading licensed medical treatment for Cushing’s syndrome.”

For the latest updates and in-depth insights into the world of Animal Health, including breakthrough treatments, industry trends, and regulatory news, contact Poppy Hodge today!